$49.00
Ipamorelin is the cleanest GHRP available — it triggers pulsatile growth hormone release without spiking cortisol, prolactin, or ACTH, making it the only growth hormone-releasing peptide appropriate for long-term use in women.
3-5 business days
SSL encrypted
Growth hormone releasing peptides (GHRPs) work by mimicking ghrelin at the GHSR receptor in the pituitary, amplifying GH pulse amplitude and suppressing somatostatin (the GH brake). Older GHRPs like GHRP-2 and GHRP-6 produced significant side effects — cortisol elevation, prolactin increase, intense hunger — that limit their utility. Ipamorelin is a fifth-generation GHRP engineered for selectivity: it activates GHSR without the off-target receptor activation that causes these side effects. The result is clean, physiological GH pulses with a minimal hormonal footprint.
For women, ipamorelin’s selective profile is not just a convenience — it’s clinically important. Female HPA axis sensitivity means cortisol elevation from GHRPs has disproportionate effects: disrupted sleep, elevated anxiety, and insulin resistance. Ipamorelin avoids this entirely, making it suitable for continuous use across cycle phases and as a standalone or stack compound. It can be used alone or combined with CJC-1295 No DAC for synergistic GH release.
Female-calibrated dosing: 100–200mcg subcutaneously at bedtime, 5 days/week. Women often respond at 100mcg. Can be run as monotherapy or stacked with CJC-1295 No DAC. Run 8–12 week cycles.
Storage: Store lyophilized powder below -20°C. After reconstitution, refrigerate at 2–8°C and use within 30 days.
| Dosage | 5mg |
|---|---|
| Format | Injectable Vial |
| Cycle Length | 8–12 weeks |
| Storage | Freeze until use. Refrigerate after reconstitution. Use within 30 days. |
Reviews
There are no reviews yet.